Your browser doesn't support javascript.
loading
Selective targeting of IL2Rßγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC.
Gadwa, Jacob; Amann, Maria; Bickett, Thomas E; Knitz, Michael W; Darragh, Laurel B; Piper, Miles; Van Court, Benjamin; Bukkapatnam, Sanjana; Pham, Tiffany T; Wang, Xiao-Jing; Saviola, Anthony J; Deak, Laura Codarri; Umaña, Pablo; Klein, Christian; D'Alessandro, Angelo; Karam, Sana D.
Afiliação
  • Gadwa J; Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA; Department of Immunology & Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Amann M; Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development (pRED), 8952 Schlieren, Switzerland.
  • Bickett TE; Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Knitz MW; Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Darragh LB; Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA; Department of Immunology & Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Piper M; Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Van Court B; Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Bukkapatnam S; Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Pham TT; Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Wang XJ; Department of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Saviola AJ; Department of Biochemistry and Molecular Genetics, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Deak LC; Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development (pRED), 8952 Schlieren, Switzerland.
  • Umaña P; Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development (pRED), 8952 Schlieren, Switzerland.
  • Klein C; Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development (pRED), 8952 Schlieren, Switzerland.
  • D'Alessandro A; Department of Biochemistry and Molecular Genetics, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Karam SD; Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA; Department of Immunology & Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA. Electronic address: sana.karam@cuanschutz.edu.
Cell Rep Med ; 4(8): 101150, 2023 08 15.
Article em En | MEDLINE | ID: mdl-37586327
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucina-2 / Neoplasias de Cabeça e Pescoço Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cell Rep Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucina-2 / Neoplasias de Cabeça e Pescoço Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cell Rep Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos